Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

被引：0
作者：
Hiroki Nakajima
Sadanori Okada
Takako Mohri
Eiichiro Kanda
Naoyuki Inaba
Yoko Hirasawa
Hiroaki Seino
Hisamoto Kuroda
Toru Hiyoshi
Tetsuji Niiya
Hitoshi Ishii
机构：
[1] Nara Medical University,Department of Diabetology
[2] Tokyo Kyosai Hospital,Department of Nephrology
[3] Tokyo Medical and Dental University,Life Science and Bioethics Research Center
[4] Shizuoka Saiseikai General Hospital,Department of Metabolism & Endocrinology
[5] Plumeria DM Clinic,Department of Internal Medicine
[6] Seino Internal Medicine Clinic,undefined
[7] Green Clinic,undefined
[8] Japanese Red Cross Medical Center,undefined
[9] Matsuyama Shimin Hospital,undefined
来源：
Diabetology & Metabolic Syndrome | / 10卷
关键词：
Type 2 diabetes mellitus; Oral hypoglycemic agent; Sodium glucose cotransporters 2 inhibitors; SGLT2 inhibitors; Dapagliflozin; Treatment satisfaction; Oral Hypoglycemic Agent-Questionnaire; Body weight; Patient reported outcome; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 189 条
  • [1] Fox CS(2010)Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study Trends Cardiovasc Med 20 90-95
  • [2] Fox CS(2004)Trends in cardiovascular complications of diabetes JAMA 292 2495-2499
  • [3] Coady S(2013)Glycemic variability: both sides of the story Diabetes Care 36 272-275
  • [4] Sorlie PD(2014)Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial Diabetes Obes Metab 16 147-158
  • [5] Levy D(2015)Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences Diab Vasc Dis Res. 12 78-89
  • [6] Meigs JB(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-2128
  • [7] D’Agostino RB(2016)Empagliflozin and progression of kidney disease in type 2 diabetes N Engl J Med 375 323-334
  • [8] Ceriello A(2017)Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 377 644-657
  • [9] Kilpatrick ES(2015)Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus Cardiovasc Diabetol. 14 142-S34
  • [10] Kovacs CS(2014)Adverse effects and safety of SGLT-2 inhibitors Diabetes Metab. 40 S28-1313
12345678910